Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21020816 | 0.86 | ALKBH3 (0.49) | KDM4EALDH1A1HPGDAHRPRKAB2 | |
| SCHEMBL2473835 | 0.86 | AHR (0.54) | TP53ALDH1A1LMNAAHRHTR2B | |
| SCHEMBL10389844 | 0.83 | MAP4K4 (0.47) | KDM4EALDH1A1LMNAHPGDNFKB1 | |
| SCHEMBL1045006 | 0.83 | AHR (0.57) | TP53AHRHSP90AB1HSD11B1DPP4 | |
| SCHEMBL7870739 | 0.81 | PTGS2 (0.44) | KDM4EALDH1A1LMNAHPGDNFKB1 | |
| SCHEMBL20241915 | 0.79 | BACE1 (0.53) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL9257913 | 0.79 | PRKAB2 (0.43) | TP53LMNAAHRHTR2BPDE4D | |
| SCHEMBL21021252 | 0.79 | PLA2G7 (0.50) | TP53KDM4EALDH1A1NFKB1NFKB2 | |
| SCHEMBL12999476 | 0.79 | ABL1 (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2AHR | |
| SCHEMBL13494486 | 0.78 | NOTUM (0.44) | KDM4EALDH1A1LMNAHPGDNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1931425-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-0087045-A1 | Process for preparing polyarylenesulphides with increased thermal and chemical resistance and improved quality of colour | BAYER AG (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0087046-A1 | Process for preparing polyarylenesulphides with increased thermal and chemical resistance | BAYER AG (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0023314-B1 | PROCESS FOR PREPARING POLY(ARYLENE SULFIDES) | BAYER AG (DE) | 1983-07-20 | — | — | EP | disclosed |
| US-4362864-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1982-12-07 | — | — | US | disclosed |
| EP-0065689-A1 | Method of producing poly(arylene sulfides) | BAYER AG (DE) | 1982-12-01 | — | — | EP | disclosed |
| US-4331801-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0040747-A2 | Process for preparing polyarylene sulfides | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
| US-4303781-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-01 | — | — | US | disclosed |
| EP-0023313-A1 | Process for preparing poly(arylene sulfides) | BAYER AG (DE) | 1981-02-04 | — | — | EP | disclosed |
| EP-0023314-A1 | Process for preparing poly(arylene sulfides) | BAYER AG (DE) | 1981-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TP53 4052/4885KDM4E 2723/4885ALDH1A1 704/4885 |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | TP53 1288/4885KDM4E 2337/4885ALDH1A1 3654/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TP53 4052/4885KDM4E 2723/4885ALDH1A1 704/4885 |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | TP53 4286/4885KDM4E 2452/4885ALDH1A1 852/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | TP53 4285/4885KDM4E 3817/4885ALDH1A1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.